Citranatal Harmony 3.0

Calcium Citrate, Iron Pentacarbonyl, Cholecalciferol, .alpha.-tocopherol, Dl-, Pyridoxine Hydrochloride, Folic Acid, Docusate Sodium, And Doconexent


Mission Pharmacal Company
Human Prescription Drug
NDC 0178-0796
Citranatal Harmony 3.0 also known as Calcium Citrate, Iron Pentacarbonyl, Cholecalciferol, .alpha.-tocopherol, Dl-, Pyridoxine Hydrochloride, Folic Acid, Docusate Sodium, And Doconexent is a human prescription drug labeled by 'Mission Pharmacal Company'. National Drug Code (NDC) number for Citranatal Harmony 3.0 is 0178-0796. This drug is available in dosage form of Capsule, Gelatin Coated. The names of the active, medicinal ingredients in Citranatal Harmony 3.0 drug includes .alpha.-tocopherol - 30 [iU]/1 Calcium Citrate - 104 mg/1 Cholecalciferol - 400 [iU]/1 Doconexent - 260 mg/1 Docusate Sodium - 50 mg/1 Folic Acid - 1 mg/1 Iron - 27 mg/1 Pyridoxine - 25 mg/1 . The currest status of Citranatal Harmony 3.0 drug is Active.

Drug Information:

Drug NDC: 0178-0796
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Citranatal Harmony 3.0
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Calcium Citrate, Iron Pentacarbonyl, Cholecalciferol, .alpha.-tocopherol, Dl-, Pyridoxine Hydrochloride, Folic Acid, Docusate Sodium, And Doconexent
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Mission Pharmacal Company
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Capsule, Gelatin Coated
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:.ALPHA.-TOCOPHEROL - 30 [iU]/1
CALCIUM CITRATE - 104 mg/1
CHOLECALCIFEROL - 400 [iU]/1
DOCONEXENT - 260 mg/1
DOCUSATE SODIUM - 50 mg/1
FOLIC ACID - 1 mg/1
IRON - 27 mg/1
PYRIDOXINE - 25 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 21 Mar, 2014
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 22 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Mission Pharmacal Company
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0301780796306
UPC stands for Universal Product Code.
NUI:M0022797
N0000175952
N0000192800
N0000005657
N0000175452
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:H4N855PNZ1
MLM29U2X85
1C6V77QF41
ZAD9OKH9JC
F05Q2T2JA0
935E97BOY8
E1UOL152H7
KV2JZ1BI6Z
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Vitamin D [EPC]
Vitamin B6 Analog [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class CS:Vitamin D [CS]
Vitamin B 6 [Chemical/Ingredient]
Analogs/Derivatives [Chemical/Ingredient]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Analogs/Derivatives [Chemical/Ingredient]
Blood Coagulation Factor [EPC]
Calcium [CS]
Cations
Divalent [CS]
Increased Coagulation Factor Activity [PE]
Vitamin B 6 [Chemical/Ingredient]
Vitamin B6 Analog [EPC]
Vitamin D [CS]
Vitamin D [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0178-0796-3030 CAPSULE, GELATIN COATED in 1 BOTTLE (0178-0796-30)21 Mar, 2014N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Citranatal harmony 3.0 calcium citrate, iron pentacarbonyl, cholecalciferol, .alpha.-tocopherol, dl-, pyridoxine hydrochloride, folic acid, docusate sodium, and doconexent gelatin calcium citrate calcium cation calcium citrate anhydrous iron iron cholecalciferol cholecalciferol .alpha.-tocopherol .alpha.-tocopherol pyridoxine pyridoxine folic acid folic acid docusate sodium docusate doconexent doconexent opaque 0796

Boxed Warning:

Warning accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. keep this product out of the reach of children. in case of accidental overdose, call a doctor or poison control center immediately.

Indications and Usage:

Indications citranatal harmony ® is a multivitamin/mineral prescription drug indicated for use in improving the nutritional status of women prior to conception, throughout pregnancy, and in the postnatal period for both lactating and nonlactating mothers.

Warnings:

Warning ingestion of more than 3 grams of omega-3 fatty acids per day has been shown to have potential antithrombotic effects, including an increased bleeding time and inr. administration of omega-3 fatty acids should be avoided in patients on anticoagulants and in those known to have an inherited or acquired bleeding diathesis. warning folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin b 12 is deficient.

Dosage and Administration:

Dosage and administration one capsule daily or as directed by a physician. store at controlled room temperature. notice contact with moisture can discolor or erode the capsule.

Contraindications:

Contraindications this product is contraindictated in patients with a known hypersensitivity to any of the ingredients.

Adverse Reactions:

Adverse reactions allergic sensitization has been reported following both oral and parenteral administration of folic acid. caution exercise caution to ensure that the prescribed dosage of dha does not exceed 1 gram (1000 mg) per day.

Description:

Description citranatal harmony ® is a prescription prenatal/postnatal multivitamin/mineral soft gelatin capsule. the prenatal vitamin is a purple, opaque soft gelatin capsule containing a greenish-gray liquid to semi-solid fill. the capsule is printed “0796” in white ink. each prenatal capsule contains: calcium (calcium citrate) 104 mg vitamin b 6 (pyridoxine hcl) 25 mg iron (ferrous fumarate, carbonyl iron) 27 mg folic acid 1 mg vitamin d 3 (cholecalciferol) 400 iu docusate sodium 50 mg vitamin e (dl-alpha tocopheryl acetate) 30 iu docosahexaenoic acid (dha 40% from 650 mg algal oil) 260 mg

How Supplied:

How supplied bottles of 30 capsules each - ndc 0178-0796-30 to report a serious adverse event or obtain product information, call (210) 696-8400 please consult your health care provider with any dietary concerns. manufactured for: mission pharmacal company san antonio, tx usa 78230 1355

Package Label Principal Display Panel:

Citranatal label ndc 0178-0796-30 label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.